Michael Sidler

Our team of scientists and product experts are on a mission: developing Sensory Intelligence to seamlessly anchor machines into physical reality. Exciting things are in the pipeline... Stay tuned! #SensoryIntelligence #FutureOfMachines

Sanity Group, a Berlin based cannabis company, is dedicated to the medicinal and health use of cannabinoids. Sanitys operations span from medicinal cannabis to consumer health and tech. We believe that everyone deserves to live a healthy life and therefore develop and distribute innovative, cannabinoid-based pharmaceuticals and wellbeing products to patients and customers around Europe. We are looking for partners with cultivation facilities around the world, that would like to expand their European footprint. You can reach our Imprint (EN) here: https://sanitygroup.com/imprint/ DE: Über diesen Link erreichen Sie unser Impressum: https://sanitygroup.com/de/impressum/ Our Careerpage: https://career.sanitygroup.com

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Infinite Roots® We are Infinite Roots®—a biotech company using fermentation and fungi to create the next generation of sustainable alternative proteins. We believe in a food system that provides accessible, tasty, and nutritious food for everyone while preserving our planet. We are a team of 60 people, from 25 different countries, speaking 15 different languages. To solve global issues, you need minds from around the world! Follow us and watch fungi and food-tech transform the food system!

Founded in late 2019 by Katrin Alberding, Clemens Raemy and Bruno Pires, kenbi is a homecare focused HealthTech company based in Berlin. Driven by the vision to create a world, where everyone is cared for, kenbi is building the first proprietary digital ecosystem around its own nurse agencies and the wider care network. Their technology reliefs nurses from administrative tasks through automation and serves patients and their families with full-circle homecare solutions accessible online. Only four years in, the company is already among the biggest private homecare solution providers in Germany, employing over 1000 nurses across West and East Germany, extending over 120,000 products & services per month. --- kenbi wurde Ende 2019 von Katrin Albering, Clemens Raemy und Bruno Pires gegründet und ist ein auf ambulante Pflege ausgerichtetes HealthTech-Unternehmen mit Sitz in Berlin. Mit der Vision, eine Welt zu schaffen, in der jede:r gut versorgt ist, baut kenbi das erste digitale Ökosystem um seine Pflegestandorte und das breitere Pflegenetzwerk herum auf. Seine Technologie entlastet das Pflegepersonal durch Automatisierung von Verwaltungsaufgaben und bietet Patientinnen, Patienten und ihren Familien online zugängliche Komplettlösungen für die Pflege zu Hause. Innerhalb von nur vier Jahren hat sich das Unternehmen zu einem der größten privaten Anbieter von ambulanten Pflegelösungen in Deutschland entwickelt und beschäftigt über 1.000 Pflegekräfte in West- und Ostdeutschland, die monatlich mehr als 120.000 Produkte & Dienstleistungen erbringen.

ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).

The biotech-company EraCal Therapeutics Ltd. is a spin-off of the University of Zurich and Harvard University, and develops first-in-class drugs to treat different diseases.

TOLREMO therapeutics AG (“TOLREMO”) is a Swiss biotechnology company that was spun out of ETH Zurich in 2017. Based on cutting-edge science and guided by pioneering real-world medicine, TOLREMO created a broad cancer drug resistance platform that provides a unique entry point into a major clinical problem. The company develops resistance-breaking add-on therapies that extend the therapeutic benefit of oncogene-targeting cancer drugs by eliminating resistance-causing persister cells (Adaptive Drug Resistance). TOLREMO’s unique drug resistance platform has the potential to catalyze a new wave of potent resistance-breaking molecules that will meaningfully extend the lives of patients suffering from cancer. To learn more visit www.tolremo.com.

Aktiia, now trading under Hilo, was established in 2018 to transform how blood pressure is measured and therefore managed. Hilo is transforming blood pressure monitoring with cuffless, AI-powered technology that delivers continuous, accessible insights for individuals and healthcare professionals. Our foundation model is trained on billions of optical signals and hundreds of millions of readings from over 120,000 users—one of the largest datasets in the field. Backed by a multidisciplinary team with deep expertise in biomedical signal processing, Hilo has contributed to over 120 peer-reviewed publications and holds more than 35 patents. Headquartered in Switzerland, we’re expanding globally to redefine how blood pressure is measured and managed.

Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data.

Versantis is a clinical-stage pharmaceutical company developing a new generation of orphan medicines to revolutionize the care of patients with liver and rare pediatric diseases. We address the unmet medical needs in emergency care. Our mission is to support acute decompensations of cirrhosis and to save infants born with rare genetic disorders.

Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company’s lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients. Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid structure biology. The Company has a partnership in place with Ono Pharmaceutical for two oncology targets. Underpinning MTx’s core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.

Lunaphore Technologies S.A., a Bio-Techne brand, is a Swiss-based life sciences company founded in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. Community guidelines available here: https://link.lunaphore.com/guidelines

Sweet vaccines are novel carbohydrate based vaccines being developed by the company Malcisbo. The first targets are unmet medical needs such as Campylobacter induced food poisoning and parasitic infections by the blood sucking stomach worm Hemonchus in sheep causing losses in food production. Malcisbo has developed a proprietary target discovery platform which it will use in combination with glycoengineering technologies to provide novel and efficient glycoconjugate vaccines. The discovery platform will generate a constant outflow of novel vaccines for unmet human and veterinary medical needs. Further projects are affordable vaccines to protect people in underdeveloped areas against parasitic worm infections.

InSphero provides superior biological relevance to in vitro testing with easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. Our patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumor tissues. These models help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. Microtissues are available directly or through a menu of 3D InSight™ Standard Services, supported by a comprehensive panel of 3D-optimized culture media, assay protocols, and imaging solutions. InSphero’s technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HTS-DILI, and validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer. Founded in 2009 and privately held, InSphero is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Our team of scientists and product experts are on a mission: developing Sensory Intelligence to seamlessly anchor machines into physical reality. Exciting things are in the pipeline... Stay tuned! #SensoryIntelligence #FutureOfMachines

Sanity Group, a Berlin based cannabis company, is dedicated to the medicinal and health use of cannabinoids. Sanitys operations span from medicinal cannabis to consumer health and tech. We believe that everyone deserves to live a healthy life and therefore develop and distribute innovative, cannabinoid-based pharmaceuticals and wellbeing products to patients and customers around Europe. We are looking for partners with cultivation facilities around the world, that would like to expand their European footprint. You can reach our Imprint (EN) here: https://sanitygroup.com/imprint/ DE: Über diesen Link erreichen Sie unser Impressum: https://sanitygroup.com/de/impressum/ Our Careerpage: https://career.sanitygroup.com

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Infinite Roots® We are Infinite Roots®—a biotech company using fermentation and fungi to create the next generation of sustainable alternative proteins. We believe in a food system that provides accessible, tasty, and nutritious food for everyone while preserving our planet. We are a team of 60 people, from 25 different countries, speaking 15 different languages. To solve global issues, you need minds from around the world! Follow us and watch fungi and food-tech transform the food system!

Founded in late 2019 by Katrin Alberding, Clemens Raemy and Bruno Pires, kenbi is a homecare focused HealthTech company based in Berlin. Driven by the vision to create a world, where everyone is cared for, kenbi is building the first proprietary digital ecosystem around its own nurse agencies and the wider care network. Their technology reliefs nurses from administrative tasks through automation and serves patients and their families with full-circle homecare solutions accessible online. Only four years in, the company is already among the biggest private homecare solution providers in Germany, employing over 1000 nurses across West and East Germany, extending over 120,000 products & services per month. --- kenbi wurde Ende 2019 von Katrin Albering, Clemens Raemy und Bruno Pires gegründet und ist ein auf ambulante Pflege ausgerichtetes HealthTech-Unternehmen mit Sitz in Berlin. Mit der Vision, eine Welt zu schaffen, in der jede:r gut versorgt ist, baut kenbi das erste digitale Ökosystem um seine Pflegestandorte und das breitere Pflegenetzwerk herum auf. Seine Technologie entlastet das Pflegepersonal durch Automatisierung von Verwaltungsaufgaben und bietet Patientinnen, Patienten und ihren Familien online zugängliche Komplettlösungen für die Pflege zu Hause. Innerhalb von nur vier Jahren hat sich das Unternehmen zu einem der größten privaten Anbieter von ambulanten Pflegelösungen in Deutschland entwickelt und beschäftigt über 1.000 Pflegekräfte in West- und Ostdeutschland, die monatlich mehr als 120.000 Produkte & Dienstleistungen erbringen.